Christian Burri

Prof. Christian Burri

Department of Medicine, Swiss Tropical & Public Health Institute, Socinstrasse 57, 4051 Basel, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in The Lancet
Verified
Journal Article
Closed access
RBReto Brun
Reto Brun
JBJohannes Blum
Johannes Blum
FCFrancois Chappuis
Francois Chappuis
Christian BurriChristian Burri
Christian Burri

1 January 2003 in Parasitology Research
Verified
Journal Article
Closed access
Christian BurriChristian Burri
Christian Burri
RBReto Brun
Reto Brun

1 July 2002 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
DLDominique Legros
Dominique Legros
GOGaëlle Ollivier
Gaëlle Ollivier
MGMarc Gastellu-Etchegorry
Marc Gastellu-Etchegorry
CPChristophe Paquet
Christophe Paquet
Christian BurriChristian Burri
Christian Burri
PBPhilippe Büscher
Philippe Büscher

1 January 2006 in Acta Tropica
Verified
Journal Article
Closed access
JBJohannes Blum
Johannes Blum
CSCaecilia Schmid
Caecilia Schmid
Christian BurriChristian Burri
Christian Burri

Verified
Journal Article
Open access
PDF file
EDEmily Dickie
Emily Dickie
FGFederica Giordani
Federica Giordani
MGMatthew Gould
Matthew Gould
PMPascal Mäser
Pascal Mäser
Christian BurriChristian Burri
Christian Burri
MBMichael P. Barrett
Michael P. Barrett
The twentieth century ended with human African trypanosomiasis (HAT) epidemics raging across many parts of Africa. Resistance to existing drugs was emerging, and many programs aiming to contain the disease had ground to a halt, given previous success against HAT and the competing priorities associated with other medical crises ravaging the continent. A series of dedicated interventions and the introduction of innovative routes to develop drugs, involving Product Development Partnerships, has led to a dramatic turnaround in the fight against HAT caused by Trypanosoma brucei gambiense. The World Health Organization have been able to optimize the use of existing tools to monitor and intervene in the disease. A promising new oral medication for stage 1 HAT, pafuramidine maleate, ultimately failed due to unforeseen toxicity issues. However, the clinical trials for this compound demonstrated the possibility of conducting such trials in the resource-poor settings of rural Africa. The Drugs for Neglected Disease initiative (DNDi), founded in 2003, has developed the first all oral therapy for both stage 1 and stage 2 HAT in fexinidazole. DNDi has also brought forward another oral therapy, acoziborole, potentially capable of curing both stage 1 and stage 2 disease in a single dosing. In this review article, we describe the remarkable successes in combating HAT through the twenty first century, bringing the prospect of the elimination of this disease into sight.

1 November 2001 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
RBReto Brun
Reto Brun
RSReto Schumacher
Reto Schumacher
CSCecile Schmid
Cecile Schmid
CKChristina Kunz
Christina Kunz
Christian BurriChristian Burri
Christian Burri
Treatment of Human African Trypanosomiasis (HAT or sleeping sickness) relies on a few drugs which are old, toxic and expensive. The most important drug for the treatment of second stage infection is melarsoprol. During the last 50 years treatment failures with melarsoprol were not a major problem in Trypanosoma brucei gambiense patients. Commonly a relapse rate of 5–8% was reported, but in recent years it has increased dramatically in some important foci of T. b. gambiense sleeping sickness. Treatment failures for T. b. rhodesiense are much less of a problem apart from some reports between 1960 and 1985 of refractoriness in T. b. rhodesiense patients in East Africa. Analysis of those isolates revealed that their in vitro sensitivity to melarsoprol was one‐tenth that of sensitive isolates, and complete failure to cure the infection in the acute mouse model with melarsoprol levels comparable with those in human patients. There was very little indication of resistance in T. b. gambiense isolates from Côte d’Ivoire and NW Uganda. The in vitro melarsoprol sensitivities for populations from relapsing and from curable patients were in the same range. Melarsoprol concentrations in the plasma and cerebrospinal fluid of patients 24 h after treatment did not show any difference between patients who relapsed and those who could be cured. The reason for relapses in the recent T. b. gambiense epidemics are not known. Other parasite‐related factors might be involved, e.g. affinity to extravascular sites other than the CNS which are less accessible to the drug. In conclusion, a combination of factors rather than a single one may be responsible for the phenomenon of melarsoprol treatment failures in T. b. gambiense patients.